AGENUS INC. Files 8-K on Security Holder Vote Matters
Ticker: AGEN · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1098972
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
AGENUS INC. is having a shareholder vote on June 11th. Big decisions ahead.
AI Summary
On June 11, 2024, AGENUS INC. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as ANTIGENICS INC /DE/, is incorporated in Delaware and headquartered in Lexington, Massachusetts.
Why It Matters
This filing indicates that AGENUS INC. is engaging its shareholders on important corporate decisions, which could impact the company's future direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Numbers
- 000-29089 — SEC File Number (Identifies the company's filing with the SEC.)
- 06-1562417 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- AGENUS INC. (company) — Registrant
- ANTIGENICS INC /DE/ (company) — Former Company Name
- June 11, 2024 (date) — Date of earliest event reported
- Lexington, Massachusetts (location) — Principal Executive Offices
- 000-29089 (other) — SEC File Number
FAQ
What specific matters are being submitted for a vote by AGENUS INC.'s security holders?
The filing states it is a 'Submission of Matters to a Vote of Security Holders' but does not specify the exact proposals in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 11, 2024.
What is AGENUS INC.'s principal executive office address?
The principal executive offices are located at 3 Forbes Road, Lexington, Massachusetts, 02421.
Has AGENUS INC. undergone a name change previously?
Yes, the company was formerly known as ANTIGENICS INC /DE/, with a date of name change on November 15, 1999.
What is the SIC code for AGENUS INC.?
The Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 725 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2024-06-14 16:02:11
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share AGEN The Nasdaq
Filing Documents
- agen-20240611.htm (8-K) — 67KB
- 0000950170-24-073614.txt ( ) — 175KB
- agen-20240611.xsd (EX-101.SCH) — 23KB
- agen-20240611_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. Agenus Inc. (the "Company") held its Annual Meeting of Stockholders on June 11, 2024 (the "Annual Meeting"). A total of 14,463,269 shares of common stock, representing 69% of the shares outstanding and eligible to vote and constituting a quorum, were present at the Annual Meeting or represented by valid proxies. At the Annual Meeting, the Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 26, 2024: (i) to elect Susan Hirsch as a Class III director for a term of three years expiring at the 2027 Annual Meeting of Stockholders ("Proposal 1"); (ii) to approve an amendment to the Company's Amended and Restated 2019 Equity Incentive Plan ("Proposal 2"); (iii) to approve an amendment to the Company's Amended and Restated Directors' Deferred Compensation Plan (as amended) to increase the number of shares of common stock authorized for issuance thereunder from 38,750 shares to 63,750 shares ("Proposal 3"); (iv) approve, in a non-binding advisory vote, the compensation of the Company's named executive officers ("Proposal 4"); and (v) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Proposal 5"). The Company's stockholders approved the Class III director nominee recommended for election in Proposal 1 at the Annual Meeting. The votes cast at the Annual Meeting were as follows: Class III Director Nominee For Withheld Broker Non-Votes Susan Hirsch 9,258,873 1,018,060 4,186,336 The Company's stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 7,717,389 2,466,405 93,139 4,186,336 The Company's stockholders approved Proposal 3. The votes cast at the Annual Meeting were as
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 14, 2024 By: /s/ Christine M. Klaskin Christine M. Klaskin, VP Finance